Jorge J. Castillo, MD, discusses preliminary data from a phase 2 study of acalabrutinib plus rituximab in patients with IgM symptomatic anti-MAG peripheral neuropathy.
These data were the results of the secondary analysis of the Ritux 3 study, as the treatment’s short-term efficacy and safety had been confirmed previously.
Lorenzo Falchi, MD, discusses the ongoing EPCORE FL-1 phase 3 trial investigating epcoritamab-rituximab-lenalidomide vs rituximab-lenalidomide in patients with relapsed or refractory follicular lymphoma.
Most patients in the cohort received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for first-line therapy; hospitalization was prevalent; and average medical and pharmacy costs were more than $140,000 per patient per year.